Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024

Business Wire

2024-11-05

REDWOOD CITY, Calif. & BOSTON, November 05, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C.

Details of the oral presentation are as follows:

Title: ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications
Session Name: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases II
Abstract Number: 1866169
Presenting Author: Monica Moreno, Ph.D.
Date and Time: November 19, 2024; 12:00 p.m. – 12:15 p.m. ET

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241105685914/en/

Contacts

Adicet Bio., Inc.
Investor and Media Contacts

Investors:
Anne Bowdidge
abowdidge@adicetbio.com

Janhavi Mohite
Precision AQ
212-362-1200
janhavi.mohite@precisionaq.com

Media:
Kerry Beth Daly
kbdaly@adicetbio.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2481085775"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2481085775\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2481085775?lang=zh_TW&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/E2BwQHr0trUKZ6AJmJh2mA--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5eba4b981214073db274dba960d3dede","is_english":true,"pubTime":"2024-11-05 20:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2481085775","market":"us","top_or_hot":-1,"title":"Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024","media":"Business Wire","content":"<html><body>\n<figure>\n<img border=\"0\" height=\"288\" src=\"https://s.yimg.com/uu/api/res/1.2/5FuMUH_BkT3oQNmYH77PhQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/5eba4b981214073db274dba960d3dede\" title=\"\" width=\"480\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>REDWOOD CITY, Calif. &amp; BOSTON, November 05, 2024</b>--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C.</p>\n<p>Details of the oral presentation are as follows:</p>\n<p><b>Title:</b> ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications<br/><b>Session Name:</b> Abstracts: Miscellaneous Rheumatic &amp; Inflammatory Diseases II<br/><b>Abstract Number:</b> 1866169<br/><b>Presenting Author:</b> Monica Moreno, Ph.D.<br/><b>Date and Time:</b> November 19, 2024; 12:00 p.m. – 12:15 p.m. ET<br/><br/><br/><br/></p>\n<p><b>About Adicet Bio, Inc.</b></p>\n<p>Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of \"off-the-shelf\" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20241105685914/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Adicet Bio., Inc. </b><br/><b>Investor and Media Contacts</b><br/></p>\n<p><b>Investors: </b><br/>Anne Bowdidge<br/>abowdidge@adicetbio.com<br/><br/></p>\n<p>Janhavi Mohite<br/>Precision AQ<br/>212-362-1200<br/>janhavi.mohite@precisionaq.com<br/><br/><br/></p>\n<p><b>Media: </b><br/>Kerry Beth Daly<br/>kbdaly@adicetbio.com<br/><br/></p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdicet Bio to Present at the American College of Rheumatology (ACR) Convergence 2024\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Business Wire</strong><span class=\"h-time small\">2024-11-05 20:00</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body>\n<figure>\n<img border=\"0\" height=\"288\" src=\"https://s.yimg.com/uu/api/res/1.2/5FuMUH_BkT3oQNmYH77PhQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/business-wire.com/5eba4b981214073db274dba960d3dede\" title=\"\" width=\"480\"/>\n<figcaption></figcaption>\n</figure>\n<p><b>REDWOOD CITY, Calif. &amp; BOSTON, November 05, 2024</b>--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C.</p>\n<p>Details of the oral presentation are as follows:</p>\n<p><b>Title:</b> ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune Indications<br/><b>Session Name:</b> Abstracts: Miscellaneous Rheumatic &amp; Inflammatory Diseases II<br/><b>Abstract Number:</b> 1866169<br/><b>Presenting Author:</b> Monica Moreno, Ph.D.<br/><b>Date and Time:</b> November 19, 2024; 12:00 p.m. – 12:15 p.m. ET<br/><br/><br/><br/></p>\n<p><b>About Adicet Bio, Inc.</b></p>\n<p>Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of \"off-the-shelf\" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20241105685914/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Adicet Bio., Inc. </b><br/><b>Investor and Media Contacts</b><br/></p>\n<p><b>Investors: </b><br/>Anne Bowdidge<br/>abowdidge@adicetbio.com<br/><br/></p>\n<p>Janhavi Mohite<br/>Precision AQ<br/>212-362-1200<br/>janhavi.mohite@precisionaq.com<br/><br/><br/></p>\n<p><b>Media: </b><br/>Kerry Beth Daly<br/>kbdaly@adicetbio.com<br/><br/></p></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/adicet-bio-present-american-college-120000102.html\">Business Wire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4117","symbol_name":"多元化保險","start_time":0,"source_url":"https://finance.yahoo.com/news/adicet-bio-present-american-college-120000102.html","article_id":"2481085775","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/E2BwQHr0trUKZ6AJmJh2mA--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5eba4b981214073db274dba960d3dede"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481085775","pubTimestamp":1730808000,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"REDWOOD CITY, Calif. & BOSTON, November 05, 2024----Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology  Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C.Title: ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune IndicationsSession Name: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases IIAbstract Number: 1866169Presenting Author: Monica Moreno, Ph.D.Date and Time: November 19, 2024; 12:00 p.m. – 12:15 p.m. ET","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4117":"多元化保险","ACET":"艾切托","AFG":"美国金融集团有限公司","BK4139":"生物科技","BK4107":"财产与意外伤害保险","BK4110":"抵押房地产投资信托","ACR":"ACRES Commercial Realty Corp."},"translate_title":"Adicet Bio将出席2024年美国风湿病学会(ACR)Convergence","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACET":0.9,"ACR":1,"AFG":1},"content_text":"REDWOOD CITY, Calif. & BOSTON, November 05, 2024--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral presentation at the upcoming American College of Rheumatology (ACR) Convergence 2024 meeting, taking place November 14-19, 2024, in Washington, D.C.\nDetails of the oral presentation are as follows:\nTitle: ADI-001: An Allogeneic CD20-targeted γδ CAR T Cell Therapy with Potential for Improved Tissue Homing in Autoimmune IndicationsSession Name: Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases IIAbstract Number: 1866169Presenting Author: Monica Moreno, Ph.D.Date and Time: November 19, 2024; 12:00 p.m. – 12:15 p.m. ET\nAbout Adicet Bio, Inc.\nAdicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of \"off-the-shelf\" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241105685914/en/\nContacts\nAdicet Bio., Inc. Investor and Media Contacts\nInvestors: Anne Bowdidgeabowdidge@adicetbio.com\nJanhavi MohitePrecision AQ212-362-1200janhavi.mohite@precisionaq.com\nMedia: Kerry Beth Dalykbdaly@adicetbio.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}